

Quarterly Data (unaudited)

Thousands of dollars, except per share amounts

	2007				
	1st	2nd	3rd	4th	Year
Revenues	\$1,501,526	\$1,575,922	\$1,631,159	\$1,651,101	\$6,359,708
Gross Profit	792,593	811,382	840,088	843,724	3,287,787
Income from Continuing Operations	131,051^(B)	235,539	240,469^(B)	249,108	856,167^(B)
Earnings per Share:					
Income from Continuing Operations	.53	.96	.98	1.02	3.50
Income from Discontinued Operations	.05	.03	.02	.04	.14
Basic Earnings per Share	.58	.99	1.00	1.07	3.63
Income from Continuing Operations	.51	.92	.95	.98	3.36
Income from Discontinued Operations	.05	.03	.02	.04	.13
Diluted Earnings per Share^(A)	.56	.95	.96	1.03	3.49
	2006				
	1st	2nd	3rd	4th	Year
Revenues	\$1,393,845	\$1,424,209	\$1,457,347	\$1,462,616	\$5,738,017
Gross Profit	727,899	725,443	737,832	753,578	2,944,752
Income from Continuing Operations	223,702	163,458 ^(C)	211,070	216,880	815,110 ^(C)
Earnings per Share:					
Income from Continuing Operations	.90	.66	.86	.88	3.30
Loss from Discontinued Operations	(.02)	(.04)	(.02)	(.17) ^(D)	(.25) ^(D)
Basic Earnings per Share^(A)	.88	.62	.84	.71	3.04
Income from Continuing Operations	.87	.63	.83	.85	3.18
Loss from Discontinued Operations	(.02)	(.04)	(.02)	(.17) ^(D)	(.24) ^(D)
Diluted Earnings per Share^(A)	.85	.60	.81	.68	2.93

(A) Total per share amounts may not add due to rounding.

(B) Includes the acquired in-process research and development charges in the first and third quarters related to the TriPath and Plaso acquisitions, respectively, as discussed in Note 3.

(C) Includes the acquired in-process research and development charge related to the GeneOhm acquisition, as discussed in Note 3.

(D) Includes the impact of the BGM exit costs, as discussed in Note 3.